| Estimated costs of production and potential prices for the WHO Essential Medicines List AM Hill, MJ Barber, D Gotham BMJ global health 3 (1), e000571, 2018 | 100 | 2018 |
| Production costs and potential prices for biosimilars of human insulin and insulin analogues D Gotham, MJ Barber, A Hill BMJ global health 3 (5), e000850, 2018 | 83 | 2018 |
| Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries MJ Barber, D Gotham, G Khwairakpam, A Hill Journal of Virus Eradication 6 (3), 100001, 2020 | 45 | 2020 |
| Global access of rifabutin for the treatment of tuberculosis–why should we prioritize this? N Rockwood, M Cerrone, M Barber, AM Hill, AL Pozniak African Journal of Reproduction and Gynaecological Endoscopy 22 (7), 2019 | 23 | 2019 |
| How the MDGs gave up on measuring access to medicines D Gotham, KH Onarheim, MJ Barber The Lancet Global Health 4 (5), e296-e297, 2016 | 22 | 2016 |
| Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List D Gotham, MJ Barber, AM Hill BMJ open 9 (9), e027780, 2019 | 19 | 2019 |
| Generic treatments for HIV, HBV, HCV, TB could be mass produced for< $90 per patient A Hill, M Barber, D Gotham, J Fortunak, S Nath, A Pozniak J Int Aids Soc 20 (Suppl 5), 2017 | 10 | 2017 |
| Open letter to the candidates for Director-General of WHO: will you support a patient-centred R&D agreement? MJ Barber, D Gotham, J Muntanyà, T Balasubramaniam The Lancet Global Health 5 (2), e135-e136, 2017 | 7 | 2017 |
| Improving affordability of new essential cancer medicines E t'Hoen, S Meyer, P Durisch, W Bannenberg, K Perehudoff, T Reed, ... Lancet Oncology 20 (8), 1052-1054, 2019 | 6 | 2019 |
| How a US-UK trade agreement could affect NHS drug prices D Gotham, MJ Barber, AM Hill BMJ 369, 2020 | 4 | 2020 |
| Potential price reductions for cancer medicines on the WHO Essential Medicines List M Barber, D Gotham, A Hill European Journal of Cancer 1 (72), S119, 2017 | 3 | 2017 |
| Hepatitis C could now be cured for under US $100 per person: analysis of mass generic production of Direct Acting Antivirals AM Hill, D Gotham, M Barber, A Pozniak, JM Fortunak Hepatology 63 (1 SUPP), 482A-482A, 2016 | 3 | 2016 |
| Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access D Gotham, M Barber, J Fortunak, A Pozniak, A Hill JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 19, 2016 | 3 | 2016 |
| COVID-19 antivirals must not affect HIV drug supply M Barber, A Sarpatwari, C Cepuch The Lancet HIV 9 (1), e7-e9, 2022 | 2 | 2022 |
| Young people have a new vision for essential medicines SR Mishra, SWS Li, KH Onarheim, F Lander, MJ Barber, A Sharma, ... The Lancet Diabetes & Endocrinology 4 (9), 733-734, 2016 | 2 | 2016 |
| Estimated sustainable cost-based prices for diabetes medicines MJ Barber, D Gotham, H Bygrave, C Cepuch JAMA Network Open 7 (3), e243474-e243474, 2024 | 1 | 2024 |
| Medicines, Markets, and the State M Barber Harvard University, 2023 | 1 | 2023 |
| The Road to Elimination of Hepatitis C: Costs Per Cure Fall to US $32 Per Person AM Hill, M Barber, G Khwairakpam, D Gotham HEPATOLOGY 70, 352A-352A, 2019 | 1 | 2019 |
| Unexplained rises in UK cancer drug prices between 2011 and 2016 A Hill, M Barber European Journal of Cancer 1 (72), S113-S114, 2017 | 1 | 2017 |
| Estimated sustainable cost-based prices for diabetes medicines| Conference Material/Poster MJ Barber, D Gotham, H Bygrave, C Cepuch MSF Scientific Days International 2024, 2024 | | 2024 |
